Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)

SAB Biotherapeutics (SABS) has disclosed Current Deferred Revenue for 4 consecutive years, with $114698.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Current Deferred Revenue fell 92.95% year-over-year to $114698.0, compared with a TTM value of $114698.0 through Sep 2024, down 92.95%, and an annual FY2023 reading of $1.3 million, changed N/A over the prior year.
  • Current Deferred Revenue was $114698.0 for Q3 2024 at SAB Biotherapeutics, roughly flat from $114698.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.9 million in Q1 2023 and bottomed at $100000.0 in Q4 2020.
  • Average Current Deferred Revenue over 4 years is $1.1 million, with a median of $377835.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue changed 0.0% in 2021, then crashed 96.04% in 2024.
  • Year by year, Current Deferred Revenue stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then skyrocketed by 1222.41% to $1.3 million in 2023, then crashed by 91.33% to $114698.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for SABS at $114698.0 in Q3 2024, $114698.0 in Q2 2024, and $377835.0 in Q1 2024.